These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28329163)

  • 1. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
    Ouwerkerk W; Voors AA; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Ter Maaten JM; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Metra M; Zwinderman AH
    Eur Heart J; 2017 Jun; 38(24):1883-1890. PubMed ID: 28329163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
    Santema BT; Ouwerkerk W; Tromp J; Sama IE; Ravera A; Regitz-Zagrosek V; Hillege H; Samani NJ; Zannad F; Dickstein K; Lang CC; Cleland JG; Ter Maaten JM; Metra M; Anker SD; van der Harst P; Ng LL; van der Meer P; van Veldhuisen DJ; Meyer S; Lam CSP; ; Voors AA
    Lancet; 2019 Oct; 394(10205):1254-1263. PubMed ID: 31447116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
    Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP
    Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.
    Ouwerkerk W; Zwinderman AH; Ng LL; Demissei B; Hillege HL; Zannad F; van Veldhuisen DJ; Samani NJ; Ponikowski P; Metra M; Ter Maaten JM; Lang CC; van der Harst P; Filippatos G; Dickstein K; Cleland JG; Anker SD; Voors AA
    J Am Coll Cardiol; 2018 Jan; 71(4):386-398. PubMed ID: 29389354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
    Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
    Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
    Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
    Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
    Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure medication dosage and survival in women and men seen at outpatient clinics.
    Bots SH; Onland-Moret NC; Tulevski II; van der Harst P; Cramer MJM; Asselbergs FW; Somsen GA; den Ruijter HM
    Heart; 2021 Nov; 107(21):1748-1755. PubMed ID: 34261736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
    Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure.
    Diamant MJ; Virani SA; MacKenzie WJ; Ignaszewski A; Toma M; Hawkins NM
    ESC Heart Fail; 2019 Aug; 6(4):774-783. PubMed ID: 31218850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
    Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
    Ter Maaten JM; Martens P; Damman K; Dickstein K; Ponikowski P; Lang CC; Ng LL; Anker SD; Samani NJ; Filippatos G; Cleland JG; Zannad F; Hillege HL; van Veldhuisen DJ; Metra M; Voors AA; Mullens W
    Clin Res Cardiol; 2020 Aug; 109(8):1048-1059. PubMed ID: 32002631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF.
    Mordi IR; Ouwerkerk W; Anker SD; Cleland JG; Dickstein K; Metra M; Ng LL; Samani NJ; van Veldhuisen DJ; Zannad F; Voors AA; Lang CC
    Eur J Heart Fail; 2021 Mar; 23(3):436-444. PubMed ID: 32216000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
    Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
    Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
    Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
    JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Starting Neurohormonal Antagonists in Patients With Acute Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Seko Y; Kato T; Morimoto T; Yaku H; Inuzuka Y; Tamaki Y; Ozasa N; Shiba M; Yamamoto E; Yoshikawa Y; Yamashita Y; Kitai T; Taniguchi R; Iguchi M; Nagao K; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Toyofuku M; Furukawa Y; Ando K; Kadota K; Sato Y; Kuwahara K; Kimura T;
    Circ J; 2022 Sep; 86(10):1547-1558. PubMed ID: 35153273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry.
    Yoshikawa Y; Tamaki Y; Morimoto T; Yaku H; Yamamoto E; Inuzuka Y; Ozasa N; Kitai T; Nagao K; Sato Y; Kondo H; Tamura T; Nakagawa Y; Kuwahara K; Kato T; Kimura T
    PLoS One; 2020; 15(9):e0239100. PubMed ID: 32925953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
    PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.